These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34834934)

  • 1. Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines.
    de Souza WM; Muraro SP; Souza GF; Amorim MR; Sesti-Costa R; Mofatto LS; Forato J; Barbosa PP; Toledo-Teixeira DA; Bispo-Dos-Santos K; Parise PL; Brunetti NS; Moreira JCO; Costa VA; Cardozo DM; Moretti ML; Barros-Mazon S; Marchesi GF; Ambrosio C; Spilki FR; Almeida VC; Vieira AS; Zambon L; Farias AS; Addas-Carvalho M; Benites BD; Marques RE; Sabino EC; Zuben ABV; Weaver SC; Faria NR; Granja F; Angerami RN; Proença-Módena JL
    Viruses; 2021 Oct; 13(11):. PubMed ID: 34834934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of an outbreak of symptomatic SARS-CoV-2 VOC 202012/01-lineage B.1.1.7 infection in healthcare workers, Italy.
    Loconsole D; Sallustio A; Accogli M; Leaci A; Sanguedolce A; Parisi A; Chironna M
    Clin Microbiol Infect; 2021 Aug; 27(8):1174.e1-1174.e4. PubMed ID: 33984489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
    Ma C; Sun W; Tang T; Jia M; Liu Y; Wan Y; Han J; Rodewald L; Li J; Song Y; Wang Y; Wu D; Wang F; Zheng H; Tang L; Gao GF; Yin Z; An Z
    Vaccine; 2022 May; 40(20):2869-2874. PubMed ID: 35400561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study.
    Souza WM; Amorim MR; Sesti-Costa R; Coimbra LD; Brunetti NS; Toledo-Teixeira DA; de Souza GF; Muraro SP; Parise PL; Barbosa PP; Bispo-Dos-Santos K; Mofatto LS; Simeoni CL; Claro IM; Duarte ASS; Coletti TM; Zangirolami AB; Costa-Lima C; Gomes ABSP; Buscaratti LI; Sales FC; Costa VA; Franco LAM; Candido DS; Pybus OG; de Jesus JG; Silva CAM; Ramundo MS; Ferreira GM; Pinho MC; Souza LM; Rocha EC; Andrade PS; Crispim MAE; Maktura GC; Manuli ER; Santos MNN; Camilo CC; Angerami RN; Moretti ML; Spilki FR; Arns CW; Addas-Carvalho M; Benites BD; Vinolo MAR; Mori MAS; Gaburo N; Dye C; Marques-Souza H; Marques RE; Farias AS; Diamond MS; Faria NR; Sabino EC; Granja F; Proença-Módena JL
    Lancet Microbe; 2021 Oct; 2(10):e527-e535. PubMed ID: 34258603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postvaccination SARS-COV-2 among Health Care Workers in New Jersey: A Genomic Epidemiological Study.
    Mathema B; Chen L; Chow KF; Zhao Y; Zody MC; Mediavilla JR; Cunningham MH; Composto K; Lee A; Oschwald DM; Germer S; Fennessey S; Patel K; Wilson D; Cassell A; Pascual L; Ip A; Corvelo A; Dar S; Kramer Y; Maniatis T; Perlin DS; Kreiswirth BN
    Microbiol Spectr; 2021 Dec; 9(3):e0188221. PubMed ID: 34787439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
    Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
    Front Immunol; 2022; 13():829665. PubMed ID: 35154152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
    Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
    EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
    Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
    J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil.
    Goes LR; Siqueira JD; Garrido MM; Alves BM; Pereira ACPM; Cicala C; Arthos J; Viola JPB; Soares MA;
    Infect Genet Evol; 2021 Oct; 94():104998. PubMed ID: 34252616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico.
    Galán-Huerta KA; Flores-Treviño S; Salas-Treviño D; Bocanegra-Ibarias P; Rivas-Estilla AM; Pérez-Alba E; Lozano-Sepúlveda SA; Arellanos-Soto D; Camacho-Ortiz A
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant.
    Fumagalli MJ; Castro-Jorge LA; de Souza WM; de Azevedo PO; Hansen AW; Gazzinelli RT; da Fonseca BAL; Spilki FR; Figueiredo LTM
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
    Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
    Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study.
    Hua Q; Zhang H; Yao P; Xu N; Sun Y; Lu H; Xu F; Liao Y; Yang J; Mao H; Zhang Y; Zhu H; Hu X; Lv H; Jiang J
    Front Immunol; 2022; 13():939311. PubMed ID: 36032136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.
    Wanlapakorn N; Suntronwong N; Phowatthanasathian H; Yorsaeng R; Thongmee T; Vichaiwattana P; Auphimai C; Wongsrisang L; Klinfueng S; Sudhinaraset N; Poovorawan Y
    Vaccine; 2022 May; 40(23):3203-3209. PubMed ID: 35465981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
    Tanriover MD; Doğanay HL; Akova M; Güner HR; Azap A; Akhan S; Köse Ş; Erdinç FŞ; Akalın EH; Tabak ÖF; Pullukçu H; Batum Ö; Şimşek Yavuz S; Turhan Ö; Yıldırmak MT; Köksal İ; Taşova Y; Korten V; Yılmaz G; Çelen MK; Altın S; Çelik İ; Bayındır Y; Karaoğlan İ; Yılmaz A; Özkul A; Gür H; Unal S;
    Lancet; 2021 Jul; 398(10296):213-222. PubMed ID: 34246358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.